247 related articles for article (PubMed ID: 18394559)
21. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC).
Kollmannsberger C; Schittenhelm M; Honecker F; Tillner J; Weber D; Oechsle K; Kanz L; Bokemeyer C
Ann Oncol; 2006 Jun; 17(6):1007-13. PubMed ID: 16533873
[TBL] [Abstract][Full Text] [Related]
22. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
Garrido G; Tikhomirov IA; Rabasa A; Yang E; Gracia E; Iznaga N; Fernández LE; Crombet T; Kerbel RS; Pérez R
Cancer Biol Ther; 2011 Feb; 11(4):373-82. PubMed ID: 21150278
[TBL] [Abstract][Full Text] [Related]
23. EGF receptor inhibition: attacks on multiple fronts.
Hubbard SR
Cancer Cell; 2005 Apr; 7(4):287-8. PubMed ID: 15837615
[TBL] [Abstract][Full Text] [Related]
24. Interaction of antibodies with ErbB receptor extracellular regions.
Schmitz KR; Ferguson KM
Exp Cell Res; 2009 Feb; 315(4):659-70. PubMed ID: 18992239
[TBL] [Abstract][Full Text] [Related]
25. GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands.
Lim Y; Yoo J; Kim MS; Hur M; Lee EH; Hur HS; Lee JC; Lee SN; Park TW; Lee K; Chang KH; Kim K; Kang Y; Hong KW; Kim SH; Kim YG; Yoon Y; Nam DH; Yang H; Kim DG; Cho HS; Won J
Mol Cancer Ther; 2016 Feb; 15(2):251-63. PubMed ID: 26586721
[TBL] [Abstract][Full Text] [Related]
26. Effects of an EGFR-binding affibody molecule on intracellular signaling pathways.
Nordberg E; Ekerljung L; Sahlberg SH; Carlsson J; Lennartsson J; Glimelius B
Int J Oncol; 2010 Apr; 36(4):967-72. PubMed ID: 20198342
[TBL] [Abstract][Full Text] [Related]
27. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.
Merchant M; Ma X; Maun HR; Zheng Z; Peng J; Romero M; Huang A; Yang NY; Nishimura M; Greve J; Santell L; Zhang YW; Su Y; Kaufman DW; Billeci KL; Mai E; Moffat B; Lim A; Duenas ET; Phillips HS; Xiang H; Young JC; Vande Woude GF; Dennis MS; Reilly DE; Schwall RH; Starovasnik MA; Lazarus RA; Yansura DG
Proc Natl Acad Sci U S A; 2013 Aug; 110(32):E2987-96. PubMed ID: 23882082
[TBL] [Abstract][Full Text] [Related]
28. Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope.
Makabe K; Yokoyama T; Uehara S; Uchikubo-Kamo T; Shirouzu M; Kimura K; Tsumoto K; Asano R; Tanaka Y; Kumagai I
Sci Rep; 2021 Mar; 11(1):5790. PubMed ID: 33707468
[TBL] [Abstract][Full Text] [Related]
29. Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000).
Schiller JH
Cancer Invest; 2008 Feb; 26(1):81-95. PubMed ID: 18181050
[TBL] [Abstract][Full Text] [Related]
30. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.
Muller YA; Chen Y; Christinger HW; Li B; Cunningham BC; Lowman HB; de Vos AM
Structure; 1998 Sep; 6(9):1153-67. PubMed ID: 9753694
[TBL] [Abstract][Full Text] [Related]
31. A collagen-binding EGFR antibody fragment targeting tumors with a collagen-rich extracellular matrix.
Liang H; Li X; Wang B; Chen B; Zhao Y; Sun J; Zhuang Y; Shi J; Shen H; Zhang Z; Dai J
Sci Rep; 2016 Feb; 6():18205. PubMed ID: 26883295
[TBL] [Abstract][Full Text] [Related]
32. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.
Cho HS; Mason K; Ramyar KX; Stanley AM; Gabelli SB; Denney DW; Leahy DJ
Nature; 2003 Feb; 421(6924):756-60. PubMed ID: 12610629
[TBL] [Abstract][Full Text] [Related]
33. Measurement of cetuximab and panitumumab-unbound serum EGFR extracellular domain using an assay based on slow off-rate modified aptamer (SOMAmer) reagents.
Park NJ; Wang X; Diaz A; Goos-Root DM; Bock C; Vaught JD; Sun W; Strom CM
PLoS One; 2013; 8(8):e71703. PubMed ID: 23990977
[TBL] [Abstract][Full Text] [Related]
34. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425.
Kamat V; Donaldson JM; Kari C; Quadros MR; Lelkes PI; Chaiken I; Cocklin S; Williams JC; Papazoglou E; Rodeck U
Cancer Biol Ther; 2008 May; 7(5):726-33. PubMed ID: 18424917
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor.
Lu C; Mi LZ; Schürpf T; Walz T; Springer TA
J Biol Chem; 2012 Nov; 287(45):38244-53. PubMed ID: 22988250
[TBL] [Abstract][Full Text] [Related]
36. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
Wu G; Barth RF; Yang W; Kawabata S; Zhang L; Green-Church K
Mol Cancer Ther; 2006 Jan; 5(1):52-9. PubMed ID: 16432162
[TBL] [Abstract][Full Text] [Related]
37. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.
Donaldson JM; Zer C; Avery KN; Bzymek KP; Horne DA; Williams JC
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17456-61. PubMed ID: 24101516
[TBL] [Abstract][Full Text] [Related]
38. Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.
Cho J; Bass AJ; Lawrence MS; Cibulskis K; Cho A; Lee SN; Yamauchi M; Wagle N; Pochanard P; Kim N; Park AK; Won J; Hur HS; Greulich H; Ogino S; Sougnez C; Voet D; Tabernero J; Jimenez J; Baselga J; Gabriel SB; Lander ES; Getz G; Eck MJ; Park WY; Meyerson M
Mol Cancer; 2014 Jun; 13():141. PubMed ID: 24894453
[TBL] [Abstract][Full Text] [Related]
39. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains.
Ogiso H; Ishitani R; Nureki O; Fukai S; Yamanaka M; Kim JH; Saito K; Sakamoto A; Inoue M; Shirouzu M; Yokoyama S
Cell; 2002 Sep; 110(6):775-87. PubMed ID: 12297050
[TBL] [Abstract][Full Text] [Related]
40. EGF receptor exposed to oxidative stress acquires abnormal phosphorylation and aberrant activated conformation that impairs canonical dimerization.
Filosto S; Khan EM; Tognon E; Becker C; Ashfaq M; Ravid T; Goldkorn T
PLoS One; 2011; 6(8):e23240. PubMed ID: 21853092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
